Elucidation of the full genetic information of Japanese rubella vaccines and the genetic changes associated with in vitro and in vivo vaccine virus phenotypes

Vaccine

Volumn 29, Issue 10, 2011, Pages 1863-1873

  Otsuki, Noriyuki ^a   Abo, Hitoshi ^a   Kubota, Toru ^a   Mori, Yoshio ^a   Umino, Yukiko ^a   Okamoto, Kiyoko ^a   Takeda, Makoto ^a   Komase, Katsuhiro ^a  

^a NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

Author keywords

Attenuation; Genome; Marker test; Rubella; Temperature sensitive

Indexed keywords

KRT VACCINE; MATSUBA VACCINE; MATSUURA VACCINE; PROTEINASE; RUBELLA VACCINE; TO 336 VACCINE; TRCB 19 VACCINE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; GENE SEQUENCE; GENOME; HUMORAL IMMUNITY; IN VITRO STUDY; IN VIVO STUDY; MUTATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN STRUCTURE; RUBELLA; TEMPERATURE SENSITIVITY; THERMOSTABILITY; VIRUS REPLICATION;

AMINO ACID SUBSTITUTION; ANIMALS; DNA MUTATIONAL ANALYSIS; GUINEA PIGS; MOLECULAR SEQUENCE DATA; MUTATION, MISSENSE; PHENOTYPE; RNA, VIRAL; RUBELLA VACCINE; RUBELLA VIRUS; SEQUENCE ANALYSIS, DNA; SERIAL PASSAGE; TEMPERATURE; VACCINES, ATTENUATED; VIRAL PROTEINS; VIRUS REPLICATION;

EID: 79951724910     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.01.016     Document Type: Article

References (45)

1. Hobman T., Chantler J. Rubella virus. Fields virology 2007, 1069-1100. Lippincott Williams & Wilkins, Philadelphia. 5th ed. D.M. Knipe, P.M. Howley, D.E. Griffin, R.A. Lamb, M.A. Martin, B. Roizman (Eds.).
2. Gregg N.M. Congenital cataract following German measles in the mother. Trans Ophthalmol Soc Aust 1941, 3:35-46.
3. Parkman P.D., Buescher E.L., Artenstein M.S. Recovery of rubella virus from army recruits. Proc Soc Exp Biol Med 1962, 111:225-230.
4. Weller T.H., Neva F.A. Propagation in tissue culture of cytopathic agents form patients with rubella-like illness. Proc Soc Exp Biol Med 1962, 111:215-225.
5. Ohtawara M., Kobune F., Umino Y., Sugiura A. Inability of Japanese rubella vaccines to induce antibody response in rabbits is due to growth restriction at 39°C. Arch Virol 1985, 83(3-4):217-227.
6. Shishido A., Ohtawara M. Development of attenuated rubella virus vaccines in Japan. Jpn J Med Sci Biol 1976, 29(October (5)):227-253.
7. Best J.M. Rubella vaccines: past, present and future. Epidemiol Infect 1991, 107(1):17-30.
8. Association of biologicals manufactures of Japan. Minimum requirements for biological products. Tokyo, 1993.
9. National Institute of Infectious Diseases. Minimum requirements for biological products. 2006 [cited; Available from: http://www.nih.go.jp/niid/MRBP/files/seibutsuki_english.pdf.
10. Dominguez G., Wang C.Y., Frey T.K. Sequence of the genome RNA of rubella virus: evidence for genetic rearrangement during togavirus evolution. Virology 1990, 177(1):225-238.
11. Pugachev K.V., Abernathy E.S., Frey T.K. Genomic sequence of the RA27/3 vaccine strain of rubella virus. Arch Virol 1997, 142(6):1165-1180.
12. Sakata M., Komase K., Nakayama T. Histidine at position 1042 of the p150 region of a KRT live attenuated rubella vaccine strain is responsible for the temperature sensitivity. Vaccine 2009, 27(2):234-242.
13. Kakizawa J., Nitta Y., Yamashita T., Ushijima H., Katow S. Mutations of rubella virus vaccine TO-336 strain occurred in the attenuation process of wild progenitor virus. Vaccine 2001, 19(20-22):2793-2802.
14. Clarke D.M., Loo T.W., Hui I., Chong P., Gillam S. Nucleotide sequence and in vitro expression of rubella virus 24S subgenomic messenger RNA encoding the structural proteins E1,E2 and C. Nucleic Acids Res 1987, 15(7):3041-3057.
15. W.H.O. Standardization of the nomenclature for genetic characteristics of wild-type rubella viruses. Wkly Epidemiol Rec 2005, 80(14):126-132.
16. Chen H.H., Stark C.J., Atreya C.D. The rubella virus nonstructural protease recognizes itself via an internal sequence present upstream of the cleavage site for trans-activity. Arch Virol 2006, 151(9):1841-1851.
17. Frey T.K. Molecular biology of rubella virus. Adv Virus Res 1994, 44:69-160.
18. Papps C.L., Tzeng W.P., Frey T.K. Evaluation of cis-acting elements in the rubella virus subgenomic RNA that play a role in its translation. Arch Virol 2005, 151(2):327-346.
19. Katow S., Minahara H., Ota T., Fukushima M. Identification of strain-specific nucleotide sequences in E1 and NS4 genes of rubella virus vaccine strains in Japan. Vaccine 1997, 15(14):1579-1585.
20. Zhou Y., Ushijima H., Frey T.K. Genomic analysis of diverse rubella virus genotypes. J Gen Virol 2007, 88(Pt 3):932-941.
21. Koonin E.V., Gorbalenya A.E., Purdy M.A., Rozanov M.N., Reyes G.R., Bradley D.W. Computer-assisted assignment of functional domains in the nonstructural polyprotein of hepatitis E virus: delineation of an additional group of positive-strand RNA plant and animal viruses. Proc Natl Acad Sci USA 1992, 89(17):8259-8263.
22. Rozanov M.N., Koonin E.V., Gorbalenya A.E. Conservation of the putative methyltransferase domain: a hallmark of the 'Sindbis-like' supergroup of positive-strand R.N.A. viruses. J. Gen Virol 1992, 73(Pt 8):2129-2134.
23. Liang Y., Yao J., Gillam S. Rubella virus nonstructural protein protease domains involved in trans- and cis-cleavage activities. J Virol 2000, 74(12):5412-5423.
24. Zhou Y., Tzeng W.P., Wong H.C., Ye Y., Jiang J., Chen Y., et al. Calcium-dependent association of calmodulin with the rubella virus nonstructural protease domain. J Biol Chem 2010, 285(12):8855-8868.
25. Sutter R.W., Kew O.M., Cochi S.L. Poliovirus vaccine-live. Vaccines 2008, 631-685. Elsevier. 5 ed. S.A. Plotkin, W.A. Orenstein, P.A. Offit (Eds.).
26. Strebel P.M., Papania M.J., Dayan G.H., Halsey N.A. Measles vaccine. Vaccine 2008, 353-398. Elsevier. 5 ed. S.A. Plotkin, W.A. Orenstein, P.A. Offit (Eds.).
27. Plotkin S.A., Rubin S.A. Mumps vaccine. Vaccine 2008, 435-465. Elsevier. 5 ed. S.A. Plotkin, W.A. Orenstein, P.A. Offit (Eds.).
28. Plotkin S.A., Reef S.E. Rubella vaccine. Vaccine 2008, 735-771. Elsevier. 5 ed. S.A. Plotkin, W.A. Orenstein, P.A. Offit (Eds.).
29. Zhou Y., Tzeng W.P., Yang W., Ye Y., Lee H.W., Frey T.K., et al. Identification of a Ca2+-binding domain in the rubella virus nonstructural protease. J Virol 2007, 81(14):7517-7528.
30. Zhou Y., Tzeng W.P., Ye Y., Huang Y., Li S., Chen Y., et al. A cysteine-rich metal-binding domain from rubella virus non-structural protein is essential for viral protease activity and virus replication. Biochem J 2009, 417(2):477-483.
31. Whitehead S.S., Juhasz K., Firestone C.Y., Collins P.L., Murphy B.R. Recombinant respiratory syncytial virus (RSV) bearing a set of mutations from cold-passaged RSV is attenuated in chimpanzees. J Virol 1998, 72(5):4467-4471.
32. Subbarao E.K., Park E.J., Lawson C.M., Chen A.Y., Murphy B.R. Sequential addition of temperature-sensitive missense mutations into the PB2 gene of influenza A transfectant viruses can effect an increase in temperature sensitivity and attenuation and permits the rational design of a genetically engineered live influenza A virus vaccine. J Virol 1995, 69(10):5969-5977.
33. Snyder M.H., Betts R.F., DeBorde D., Tierney E.L., Clements M.L., Herrington D., et al. Four viral genes independently contribute to attenuation of live influenza A/Ann Arbor/6/60 (H2N2) cold-adapted reassortant virus vaccines. J Virol 1988, 62(2):488-495.
34. Skiadopoulos M.H., Surman S., Tatem J.M., Paschalis M., Wu S.L., Udem S.A., et al. Identification of mutations contributing to the temperature-sensitive, cold-adapted, and attenuation phenotypes of the live-attenuated cold-passage 45 (cp45) human parainfluenza virus 3 candidate vaccine. J Virol 1999, 73(2):1374-1381.
35. Skiadopoulos M.H., Durbin A.P., Tatem J.M., Wu S.L., Paschalis M., Tao T., et al. Three amino acid substitutions in the L protein of the human parainfluenza virus type 3 cp45 live attenuated vaccine candidate contribute to its temperature-sensitive and attenuation phenotypes. J Virol 1998, 72(3):1762-1768.
36. Crowe J.E., Bui P.T., Siber G.R., Elkins W.R., Chanock R.M., Murphy B.R. Cold-passaged, temperature-sensitive mutants of human respiratory syncytial virus (RSV) are highly attenuated, immunogenic, and protective in seronegative chimpanzees, even when RSV antibodies are infused shortly before immunization. Vaccine 1995, 13(9):847-855.
37. Hall S.L., Stokes A., Tierney E.L., London W.T., Belshe R.B., Newman F.C., et al. Cold-passaged human parainfluenza type 3 viruses contain ts and non-ts mutations leading to attenuation in rhesus monkeys. Virus Res 1992, 22(3):173-184.
38. Juhasz K., Whitehead S.S., Bui P.T., Biggs J.M., Crowe J.E., Boulanger C.A., et al. The temperature-sensitive (ts) phenotype of a cold-passaged (cp) live attenuated respiratory syncytial virus vaccine candidate, designated cpts530, results from a single amino acid substitution in the L protein. J Virol 1997, 71(8):5814-5819.
39. Komase K., Nakayama T., Iijima M., Miki K., Kawanishi R., Uejima H. The phosphoprotein of attenuated measles AIK-C vaccine strain contributes to its temperature-sensitive phenotype. Vaccine 2006, 24(6):826-834.
40. Palese P. The genes of influenza virus. Cell 1977, 10(1):1-10.
41. Gombold J.L., Estes M.K., Ramig R.F. Assignment of simian rotavirus SA11 temperature-sensitive mutant groups B and E to genome segments. Virology 1985, 143(1):309-320.
42. Sparks J.S., Donaldson E.F., Lu X., Baric R.S., Denison M.R. A novel mutation in murine hepatitis virus nsp5, the viral 3C-like proteinase, causes temperature-sensitive defects in viral growth and protein processing. J Virol 2008, 82(12):5999-6008.
43. Lulla V., Merits A., Sarin P., Kaariainen L., Keranen S., Ahola T. Identification of mutations causing temperature-sensitive defects in Semliki Forest virus RNA synthesis. J Virol 2006, 80(6):3108-3111.
44. Suomalainen M., Garoff H., Baron M.D. The E2 signal sequence of rubella virus remains part of the capsid protein and confers membrane association in vitro. J Virol 1990, 64(11):5500-5509.
45. Yao J., Gillam S. Mutational analysis, using a full-length rubella virus cDNA clone, of rubella virus E1 transmembrane and cytoplasmic domains required for virus release. J Virol 1999, 73(6):4622-4630.